1622848-92-3 Usage
Description
(S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide, also known as GSK2982772, is a first-in-class receptor interacting protein 1 (RIP1)-kinase specific clinical candidate. It is a potent inhibitor of RIP1, which plays a crucial role in regulating necroptosis and inflammation. (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide has shown significant potential in treating various human pathologies, particularly immune-mediated inflammatory diseases. Its ability to block many TNF-dependent cellular responses and reduce the spontaneous production of cytokines from human ulcerative colitis explants highlights its potential as a novel anti-inflammatory agent.
Uses
Used in Pharmaceutical Industry:
(S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide is used as an anti-inflammatory agent for its ability to inhibit the receptor interacting protein 1 (RIP1) and regulate necroptosis and inflammation. This makes it a promising candidate for the treatment of immune-mediated inflammatory diseases.
Used in Clinical Research:
In the field of clinical research, (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide is used as a specific clinical candidate for studying its efficacy and safety in treating inflammatory diseases. Its potential to block TNF-dependent cellular responses and reduce cytokine production makes it a valuable tool for understanding the underlying mechanisms of inflammation and developing new therapeutic strategies.
Used in Drug Development:
(S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-1H-1,2,4-triazole-3-carboxamide is utilized in drug development as a lead compound for the creation of new anti-inflammatory medications. Its specificity for RIP1-kinase and its effectiveness in blocking TNF-dependent responses make it a valuable starting point for designing and synthesizing novel drugs targeting inflammatory pathways.
References
Harris, P. A., et al. "Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases." Journal of Medicinal Chemistry 60.4(2017):1247-1261.
Jeong, Jae Uk, et al. "Synthesis of ( S )-3-amino-benzo[ b ][1,4]oxazepin-4-one via Mitsunobu and S N Ar reaction for a first-in-class RIP1 kinase inhibitor GSK2982772 in clinical trials." Tetrahedron Letters 58.23(2017):2306-2308.
Check Digit Verification of cas no
The CAS Registry Mumber 1622848-92-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,2,2,8,4 and 8 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1622848-92:
(9*1)+(8*6)+(7*2)+(6*2)+(5*8)+(4*4)+(3*8)+(2*9)+(1*2)=183
183 % 10 = 3
So 1622848-92-3 is a valid CAS Registry Number.